Long-term visual outcomes for treatment of submacular haemorrhage secondary to polypoidal choroidal vasculopathy

Hyun Goo Kang, Hyunseung Kang, Suk Ho Byeon, Sung Soo Kim, Hyoung Jun Koh, Sung Chul Lee, Min Kim

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Importance: There is no consensus on the optimal management of submacular haemorrhage (SMH) secondary to polypoidal choroidal vasculopathy (PCV). Background: To compare the long-term outcome of three treatment strategies for PCV with SMH. Design: Retrospective case series at two tertiary hospitals. Samples: A total of 48 consecutive eyes treated between July 2006 and March 2016. Methods: Patients were grouped according to the treatment received: 22 eyes with intravitreal bevacizumab (IVB), 14 with a combination of IVB and pneumatic displacement (PD) and 12 with IVB and vitrectomy (TPPV). Main Outcome Measures: Change in best-corrected visual acuity (BCVA) at onset and up to 24 months. Secondary measures included demographic data, imaging data and complications. Results: Comparing the mean BCVAs of the groups revealed significant differences only at month 1 (P = 0.005). Changes in the mean BCVA over time revealed no significance in the resulting final BCVA (P = 0.062), which was 20 out of 155 (logMAR 0.89 ± 0.64) for IVB monotherapy, 20 out of 174 (0.94 ± 1.04) for combined IVB + PD, and 20 out of 195 (0.99 ± 0.90) for combined IVB + TPPV eyes. Sustained long-term improvement of over three Snellen lines was found in seven (31.82%) IVB monotherapy, 10 (71.43%) combined IVB + PD, and seven (58.33%) combined IVB + TPPV eyes (P = 0.043). SMH recurrence was observed in two eyes after IVB monotherapy and one eye after combined IVB + PD (P = 0.786). Conclusions and Relevance: IVB monotherapy appears to be as effective as combination therapies for treating SMH secondary to PCV with regards to BCVA at 24 months, and may be a cost-effective strategy for long-term management.

Original languageEnglish
Pages (from-to)916-925
Number of pages10
JournalClinical and Experimental Ophthalmology
Volume46
Issue number8
DOIs
Publication statusPublished - 2018 Nov

Fingerprint

Hemorrhage
Visual Acuity
Bevacizumab
Vitrectomy
Tertiary Care Centers
Consensus
Demography
Outcome Assessment (Health Care)
Costs and Cost Analysis
Recurrence
Therapeutics

All Science Journal Classification (ASJC) codes

  • Ophthalmology

Cite this

Kang, Hyun Goo ; Kang, Hyunseung ; Byeon, Suk Ho ; Kim, Sung Soo ; Koh, Hyoung Jun ; Lee, Sung Chul ; Kim, Min. / Long-term visual outcomes for treatment of submacular haemorrhage secondary to polypoidal choroidal vasculopathy. In: Clinical and Experimental Ophthalmology. 2018 ; Vol. 46, No. 8. pp. 916-925.
@article{7361f3d7afc345da8eedf5a08a37faee,
title = "Long-term visual outcomes for treatment of submacular haemorrhage secondary to polypoidal choroidal vasculopathy",
abstract = "Importance: There is no consensus on the optimal management of submacular haemorrhage (SMH) secondary to polypoidal choroidal vasculopathy (PCV). Background: To compare the long-term outcome of three treatment strategies for PCV with SMH. Design: Retrospective case series at two tertiary hospitals. Samples: A total of 48 consecutive eyes treated between July 2006 and March 2016. Methods: Patients were grouped according to the treatment received: 22 eyes with intravitreal bevacizumab (IVB), 14 with a combination of IVB and pneumatic displacement (PD) and 12 with IVB and vitrectomy (TPPV). Main Outcome Measures: Change in best-corrected visual acuity (BCVA) at onset and up to 24 months. Secondary measures included demographic data, imaging data and complications. Results: Comparing the mean BCVAs of the groups revealed significant differences only at month 1 (P = 0.005). Changes in the mean BCVA over time revealed no significance in the resulting final BCVA (P = 0.062), which was 20 out of 155 (logMAR 0.89 ± 0.64) for IVB monotherapy, 20 out of 174 (0.94 ± 1.04) for combined IVB + PD, and 20 out of 195 (0.99 ± 0.90) for combined IVB + TPPV eyes. Sustained long-term improvement of over three Snellen lines was found in seven (31.82{\%}) IVB monotherapy, 10 (71.43{\%}) combined IVB + PD, and seven (58.33{\%}) combined IVB + TPPV eyes (P = 0.043). SMH recurrence was observed in two eyes after IVB monotherapy and one eye after combined IVB + PD (P = 0.786). Conclusions and Relevance: IVB monotherapy appears to be as effective as combination therapies for treating SMH secondary to PCV with regards to BCVA at 24 months, and may be a cost-effective strategy for long-term management.",
author = "Kang, {Hyun Goo} and Hyunseung Kang and Byeon, {Suk Ho} and Kim, {Sung Soo} and Koh, {Hyoung Jun} and Lee, {Sung Chul} and Min Kim",
year = "2018",
month = "11",
doi = "10.1111/ceo.13198",
language = "English",
volume = "46",
pages = "916--925",
journal = "Clinical and Experimental Ophthalmology",
issn = "1442-6404",
publisher = "Wiley-Blackwell",
number = "8",

}

Long-term visual outcomes for treatment of submacular haemorrhage secondary to polypoidal choroidal vasculopathy. / Kang, Hyun Goo; Kang, Hyunseung; Byeon, Suk Ho; Kim, Sung Soo; Koh, Hyoung Jun; Lee, Sung Chul; Kim, Min.

In: Clinical and Experimental Ophthalmology, Vol. 46, No. 8, 11.2018, p. 916-925.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Long-term visual outcomes for treatment of submacular haemorrhage secondary to polypoidal choroidal vasculopathy

AU - Kang, Hyun Goo

AU - Kang, Hyunseung

AU - Byeon, Suk Ho

AU - Kim, Sung Soo

AU - Koh, Hyoung Jun

AU - Lee, Sung Chul

AU - Kim, Min

PY - 2018/11

Y1 - 2018/11

N2 - Importance: There is no consensus on the optimal management of submacular haemorrhage (SMH) secondary to polypoidal choroidal vasculopathy (PCV). Background: To compare the long-term outcome of three treatment strategies for PCV with SMH. Design: Retrospective case series at two tertiary hospitals. Samples: A total of 48 consecutive eyes treated between July 2006 and March 2016. Methods: Patients were grouped according to the treatment received: 22 eyes with intravitreal bevacizumab (IVB), 14 with a combination of IVB and pneumatic displacement (PD) and 12 with IVB and vitrectomy (TPPV). Main Outcome Measures: Change in best-corrected visual acuity (BCVA) at onset and up to 24 months. Secondary measures included demographic data, imaging data and complications. Results: Comparing the mean BCVAs of the groups revealed significant differences only at month 1 (P = 0.005). Changes in the mean BCVA over time revealed no significance in the resulting final BCVA (P = 0.062), which was 20 out of 155 (logMAR 0.89 ± 0.64) for IVB monotherapy, 20 out of 174 (0.94 ± 1.04) for combined IVB + PD, and 20 out of 195 (0.99 ± 0.90) for combined IVB + TPPV eyes. Sustained long-term improvement of over three Snellen lines was found in seven (31.82%) IVB monotherapy, 10 (71.43%) combined IVB + PD, and seven (58.33%) combined IVB + TPPV eyes (P = 0.043). SMH recurrence was observed in two eyes after IVB monotherapy and one eye after combined IVB + PD (P = 0.786). Conclusions and Relevance: IVB monotherapy appears to be as effective as combination therapies for treating SMH secondary to PCV with regards to BCVA at 24 months, and may be a cost-effective strategy for long-term management.

AB - Importance: There is no consensus on the optimal management of submacular haemorrhage (SMH) secondary to polypoidal choroidal vasculopathy (PCV). Background: To compare the long-term outcome of three treatment strategies for PCV with SMH. Design: Retrospective case series at two tertiary hospitals. Samples: A total of 48 consecutive eyes treated between July 2006 and March 2016. Methods: Patients were grouped according to the treatment received: 22 eyes with intravitreal bevacizumab (IVB), 14 with a combination of IVB and pneumatic displacement (PD) and 12 with IVB and vitrectomy (TPPV). Main Outcome Measures: Change in best-corrected visual acuity (BCVA) at onset and up to 24 months. Secondary measures included demographic data, imaging data and complications. Results: Comparing the mean BCVAs of the groups revealed significant differences only at month 1 (P = 0.005). Changes in the mean BCVA over time revealed no significance in the resulting final BCVA (P = 0.062), which was 20 out of 155 (logMAR 0.89 ± 0.64) for IVB monotherapy, 20 out of 174 (0.94 ± 1.04) for combined IVB + PD, and 20 out of 195 (0.99 ± 0.90) for combined IVB + TPPV eyes. Sustained long-term improvement of over three Snellen lines was found in seven (31.82%) IVB monotherapy, 10 (71.43%) combined IVB + PD, and seven (58.33%) combined IVB + TPPV eyes (P = 0.043). SMH recurrence was observed in two eyes after IVB monotherapy and one eye after combined IVB + PD (P = 0.786). Conclusions and Relevance: IVB monotherapy appears to be as effective as combination therapies for treating SMH secondary to PCV with regards to BCVA at 24 months, and may be a cost-effective strategy for long-term management.

UR - http://www.scopus.com/inward/record.url?scp=85045954844&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045954844&partnerID=8YFLogxK

U2 - 10.1111/ceo.13198

DO - 10.1111/ceo.13198

M3 - Article

C2 - 29652440

AN - SCOPUS:85045954844

VL - 46

SP - 916

EP - 925

JO - Clinical and Experimental Ophthalmology

JF - Clinical and Experimental Ophthalmology

SN - 1442-6404

IS - 8

ER -